Pressure BioSciences (PBIO) 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 11, 2016
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,868,862
Trading Symbol	PBIO
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 41,939	$ 116,783
Accounts receivable	589,682	113,256
Inventories, net of $50,000 reserve at September 30, 2016 and December 31, 2015	1,008,138	1,038,371
Prepaid income taxes	7,405	7,381
Prepaid expenses and other current assets	179,954	213,926
Total current assets	1,827,118	1,489,717
Investment in available-for-sale equity securities	59,550	294,522
Property and equipment, net	7,933	20,149
TOTAL ASSETS	1,894,601	1,804,388
CURRENT LIABILITIES
Accounts payable	532,214	941,389
Accrued employee compensation	185,909	176,009
Accrued professional fees and other	690,230	821,088
Deferred revenue	270,102	140,878
Convertible debt, net of unamortized debt discounts of $1,891,206 at September 30, 2016 and $0 at December 31, 2015	2,664,334	100,000
Other debt, net of unamortized discounts of $5,183 and $3,041, respectively	242,963	151,628
Warrant derivative liability	4,325,864	3,295,976
Conversion option derivative liability	4,627,452	3,940,791
Total current liabilities	13,539,068	9,567,759
LONG TERM LIABILITIES
Related party convertible debt, net of unamortized debt discounts of $199,436 and $0, respectively	91,568
Convertible debt, net of unamortized debt discounts of $2,076,658 and $5,223,658, respectively	986,843	177,342
Deferred revenue	36,935	36,935
TOTAL LIABILITIES	14,654,414	9,782,036
STOCKHOLDERS’ DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 30,599,839 and 23,004,898 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	305,998	230,050
Warrants to acquire common stock	5,683,897	5,416,681
Additional paid-in capital	27,080,191	26,036,733
Accumulated other comprehensive income	(339,997)	(105,025)
Accumulated deficit	(45,490,974)	(39,557,206)
Total stockholders’ deficit	(12,759,813)	(7,977,648)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,894,601	1,804,388
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	866	866
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	35	36
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	$ 68	$ 114

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventories reserve	$ 50,000	$ 50,000
Convertible debt, current unamortized discounts	1,891,206	0
Other debt, unamortized discounts net	5,183	3,041
Convertible debt related party unamortized debt discount net	199,436	0
Convertible debt, non current unamortized discounts	$ 2,076,658	$ 5,223,658
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, shares issued	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,599,839	23,004,898
Common stock, shares outstanding	30,599,839	23,004,898
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ .01	$ .01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	86,570	86,570
Convertible preferred stock, shares outstanding	86,570	86,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,521	3,546
Convertible preferred stock, shares outstanding	3,521	3,546
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	6,816	11,416
Convertible preferred stock, shares outstanding	6,816	11,416

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Products, services, other	$ 500,949	$ 481,452	$ 1,429,487	$ 1,174,391
Grant revenue	34,385	98,882	127,289	259,181
Total revenue	535,334	580,334	1,556,776	1,433,572
Costs and expenses:
Cost of products and services	262,894	209,804	727,698	575,780
Research and development	268,317	355,574	925,015	878,899
Selling and marketing	224,380	207,888	609,501	574,289
General and administrative	231,550	497,796	1,853,010	2,034,040
Total operating costs and expenses	987,141	1,271,062	4,115,224	4,063,008
Operating loss	(451,807)	(690,728)	(2,558,448)	(2,629,436)
Other (expense) income:
Interest expense, net	(1,116,328)	(1,584,830)	(2,961,708)	(2,831,106)
Other expense	(200)		(1,112)	(36,910)
Gain on extinguishment of embedded derivative liabilities		1,180,251		2,028,324
Change in fair value of derivative liabilities	623,128	437,379	(412,500)	38,968
Total other (expense) income	(493,400)	32,800	(3,375,320)	(800,724)
Net loss	(945,207)	(657,928)	(5,933,768)	(3,430,160)
Accrued dividends on convertible preferred stock		1,711		(21,768)
Net loss applicable to common shareholders	$ (945,207)	$ (656,217)	$ (5,933,768)	$ (3,451,928)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.03)	$ (0.03)	$ (0.23)	$ (0.17)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	29,425,362	20,737,827	26,139,740	19,771,323

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Comprehensive Loss
Net loss	$ (945,207)	$ (657,928)	$ (5,933,768)	$ (3,430,160)
Other comprehensive loss
Unrealized loss on marketable securities	(22,233)		(234,972)
Comprehensive loss	$ (967,440)	$ (657,928)	$ (6,168,740)	$ (3,430,160)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,933,768)	$ (3,430,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,489	18,279
Accretion of interest and amortization of debt discount	2,848,058	2,367,381
Penalty interest added to debt principal	41,200
Gain on settlement of debt	(5,044)
Stock-based compensation expense	282,811	185,370
Amortization of third party fees paid in common stock and warrants	332,700	173,538
Gain on extinguishment of embedded derivative liabilities		(2,028,324)
Change in fair value of derivative liabilities	412,500	(38,968)
Changes in operating assets and liabilities:
Accounts receivable	(476,426)	(90,800)
Inventories	30,233	41,709
Prepaid expenses and other assets	33,948	123,808
Accounts payable	(409,175)	(200,969)
Accrued employee compensation	9,900	48,606
Deferred revenue and other accrued expenses	80,058	150,581
Net cash used in operating activities	(2,737,516)	(2,679,949)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(3,273)	(6,662)
Net cash used in investing activities	(3,273)	(6,662)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from related party convertible debt	96,667	6,300
Payments on related party debt		(12,300)
Net proceeds from convertible debt	2,102,382	3,991,437
Payments on convertible debt		(2,107,065)
Net proceeds from non-convertible debt	865,152	1,300,000
Payments on non-convertible debt	(781,221)	(537,641)
Net proceeds from the issuance of common stock	382,965
Payment of prepayment penalty		(351,193)
Net cash provided by financing activities	2,665,945	2,289,538
NET DECREASE IN CASH	(74,844)	(397,073)
CASH AT BEGINNING OF YEAR	116,783	473,948
CASH AT END OF PERIOD	41,939	76,875
SUPPLEMENTAL INFORMATION
Interest paid in cash	1,154	239,389
Income taxes paid in cash
NON CASH TRANSACTIONS:
Convertible debt exchanged for common stock	117,837	338,000
Cashless exercise of warrants	11,100
Discount due to beneficial conversion feature	20,721
Discount due to warrants issued with debt	39,755
Common stock issued with debt	104,731
Common stock issued to settle non-convertible debt	41,200
Conversion of preferred stock into common stock	63,904
Extension fees added to principal		84,000
Issuance of common stock for investment in available-for-sale equity securities		399,547
Accrued dividends on preferred stock		21,768
Unrealized loss from available-for-sale equity securities	234,972	76,687
Debt discount from derivative liability	1,304,049	5,085,536
Prepayment penalty and accrued interest enrolled into debt principal		$ 48,950

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure BioSciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming and, in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking – the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels i.e., 35,000 pounds per square inch (“ psi Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“ DNA RNA ® PULSE PCT SPS In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities but is expected to commence operations in 2017. Therefore, we don’t have control of the subsidiary and did not consolidate in our financial statements.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2016
Going Concern
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2016, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Note 6, we completed an over-subscribed $5.0 million debt financing on March 31, 2016 with a total amount raised of $6.3 million. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the nine months ended September 30, 2016 we received $3,447,166 net proceeds, in additional convertible, non-convertible debt and shares of common stock. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. We need substantial additional capital to fund normal operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. These financial statements do not include any adjustments that might result from this uncertainty.

Interim Financial Reporting

Interim Financial Reporting	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Interim Financial Reporting	3) Interim Financial Reporting The accompanying unaudited condensed consolidated balance sheet as of December 31, 2015, which was derived from audited financial statements, and the unaudited interim condensed consolidated financial statements of Pressure BioSciences, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all material adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2015 as filed with the Securities and Exchange Commission on April 5, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4) Summary of Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Reclassifications Certain amounts in the 2015 consolidated financial statements have been reclassified to conform to the 2016 presentation. Use of Estimates To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2016 and 2015. For the Three Months Ended September 30, 2016 2015 Top Five Customers 60 % 43 % Federal Agencies 9 % 2 % For the Nine Months Ended September 30, 2016 2015 Top Five Customers 31 % 34 % Federal Agencies 3 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2016 and December 31, 2015: September 30, 2016 December, 31, 2015 Top Five Customers 55 % 93 % Federal Agencies 9 % 1 % Product Supply A Massachusetts-based contract manufacturer started building the new NEP2320 Extreme Barocycler instrument in May 2016. We plan to have this manufacturer build all instruments in the future. Investment in Available-For-Sale Equity Securities As of September 30, 2016, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory is as follows: September 30, 2016 December 31, 2015 Raw materials $ 491,254 $ 310,367 Finished goods 566,884 778,004 Inventory Reserve (50,000 ) (50,000 ) Total $ 1,008,138 $ 1,038,371 Debt Issuance Costs In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2016 and 2015: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Numerator: Net loss $ (945,207 ) $ (657,928 ) $ (5,933,768 ) $ (3,430,160 ) Preferred dividends accrued — 1,711 — (21,768 ) Net loss applicable to common shareholders $ (945,207 ) $ (656,217 ) $ (5,933,768 ) $ (3,451,928 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 29,425,362 20,737,827 26,139,740 19,771,323 Income (loss) per common share – basic and diluted $ (0.03 ) $ (0.03 ) $ (0.23 ) $ (0.17 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of September 30, 2016 2015 Stock options 5,269,250 3,201,250 Convertible debt 26,971,732 26,015,029 Common stock warrants 24,824,695 26,125,127 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 2,100,000 Series J Convertible Preferred Stock 3,521,000 3,546,000 Series K Convertible Preferred Stock 6,816,000 11,399,000 72,118,377 75,002,106 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $90,500 and $74,864 for the three months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2016 2015 Research and development $ 14,735 $ 18,307 Selling and marketing 9,911 13,310 General and administrative 65,854 43,247 Total stock-based compensation expense $ 90,500 $ 74,864 The Company recognized stock-based compensation expense of $282,811 and $185,370 for the nine months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30 2016 2015 Research and development $ 50,766 $ 41,172 Selling and marketing 32,404 27,386 General and administrative 199,641 116,812 Total stock-based compensation expense $ 282,811 $ 185,370 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue with carrying values that approximate fair value. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2016: Fair value measurements at September 30, 2016 using: September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 59,550 $ 59,550 $ - $ - Total Financial Assets $ 59,550 $ 59,550 $ - $ - September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 189,884 $ — $ — $ 189,884 Warrants Issued with Convertible Debt 4,135,980 — — 4,135,980 Conversion Option Derivative Liabilities 4,627,452 — — 4,627,452 Total Derivatives $ 8,953,316 $ — $ — $ 8,953,316 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the nine months ended September 30, 2016: December 31,2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2016 Available-For-Sale Equity Securities $ 294,522 $ - $ (234,972 ) $ — $ 59,550 Total Financial Assets $ 294,522 $ — $ (234,972 ) $ — $ 59,550 December 31, 2015 Issuance fair value Change in fair value September 30, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ — $ 16,358 $ 189,884 Convertible Debt Warrants 3,122,450 1,094,432 (80,902 ) 4,135,980 Conversion Option Liabilities 3,940,791 1,547,127 (860,466 ) 4,627,452 Total Derivatives $ 7,236,767 $ 2,641,559 $ (925,010 ) $ 8,953,316 The amounts above valued at issuance includes $1,337,510 that was charged directly to “change in fair value of derivative liabilities” at issuance. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015: Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 294,522 $ 294,522 $ — $ — Total Financial Assets $ 294,522 $ 294,522 $ — $ — December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 $ — $ — $ 173,526 Warrants Issued with Convertible Debt 3,122,450 — — 3,122,450 Conversion Option Derivative Liabilities 3,940,791 — — 3,940,791 Total Derivatives $ 7,236,767 $ — $ — $ 7,236,767 The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 60.0 11.0 8.0 Expected volatility 104.5 % 104.9 % 92.4 % Risk-free interest rate 0.875 % 0.65 % 0.45 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.18 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the period reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 36.0-60.0 55.0-60.0 46.0-54.0 Expected volatility 114.3 - 138.3 % 136.3-141.6 % 116.2 -137.4 % Risk-free interest rate 0.86-1.69 % 1.29-1.76 % 1.01 % Exercise price $ 00.40-$0.42 0.40 $ 0.40 Fair value per warrant $ 0.19-$0.40 0.30 $ 0.30-$1.35 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2015 Conversion options revalued at September 30, 2016 Expected life (in months) 3-24 18-24 10-18 Expected volatility 97.6-153.8 % 112.2-114.7 % 94.3%-96.6 % Risk-free interest rate 0.37-0.99 % 1.06 % 0.59-0.77 % Exercise price $ 0.24-$0.45 $ 0.28 $ 0.28 Fair value per conversion option $ 0.07-$0.30 $ 0.14-$0.33 $ 0.17-$0.21

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5) Commitments and Contingencies Operating Leases Our corporate offices are currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $4,800 per month, on a lease extension, signed on December 29, 2015, that expires December 31, 2016, for our corporate office. On November 1, 2014 we signed a lease for lab space in Medford, MA. We subsequently expanded our space in Medford. The lease expires December 30, 2017 and requires monthly payments of $5,385 subject to annual cost of living increases. Rental costs are expensed as incurred. During the nine months ended September 30, 2016 and 2015 we incurred $108,038 and $73,775 in rent expense, respectively for the use of our corporate office and research and development facilities. Government Grants We have received a $1.05 million NIH SBIR Phase II Grant. Under the grant, the NIH has committed to pay the Company to develop a high-throughput, high pressure-based DNA Shearing System for Next Generation Sequencing and other genomic applications. The grant terminates in November 2017.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	6) Convertible Debt and Other Debt Senior Secured Convertible Debentures and Warrants We entered into Subscription Agreements (the “ Subscription Agreement Purchaser Debentures Warrants Purchase Price The Company issued a principal aggregate amount of $6,962,504 in Debentures which includes a 10% original issue discount on the Purchase Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance. The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares of the Company’s common stock at a fixed conversion price equal to $0.28 per share, subject to applicable adjustments. In the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock, at the Company’s discretion. At any time after the Issuance Date, the Company has the option, subject to certain conditions, to redeem some or all of the then outstanding principal amount of the Debenture for cash in an amount equal to the sum of (i) 120% of the then outstanding principal amount of the Debenture, (ii) accrued but unpaid interest and (iii) any liquidated damages and other amounts due in respect of the Debenture. The Company issued warrants exercisable into a total of 11,302,766 shares of our common stock. The Warrants issued in this transaction are immediately exercisable at an exercise price of $0.40 per share, subject to applicable adjustments including full ratchet anti-dilution in the event that we issue any securities at a price lower than the exercise price then in effect. The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales below the exercise price. Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTC QB Market (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days. In connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment, performance and discharge in full of all of Company’s obligations under the Debentures, Warrants and the other Transaction Documents. The Company determined that the conversion feature of the Debentures met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and are amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the condensed consolidated balance sheets. The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company’s condensed consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds are offset by debt discounts, which are amortized to interest expense over the expected life of the debt. ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two year term of these loans. We amortized $2,768,527 of the debt discount to interest expense in 2016. The warrants issued in connection with the convertible debentures are classified as warrant derivative liabilities because the warrants are entitled to certain rights in subsequent financings and the warrants contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $2,847,624 to the total warrants out of the gross proceeds of $6,329,549. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. Other convertible notes On May 13, 2016, one lender converted an outstanding note issued on April 28, 2015 and the related accrued interest totaling $117,837 to 420,849 common shares. As of September 30, 2016, the outstanding balance on the note was zero. On May 24, we sold an additional convertible note for $107,000 with warrants to purchase 50,000 shares of common stock at an exercise price of $0.55 per share. The purchaser has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $12,406 to the total warrants and the recognition of a beneficial conversion feature of $7,962, both of which were recorded as a discount to the note. We evaluated the convertible note and warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. On June 14, 2016, we sold an additional convertible note for $115,000 and issued 30,667 common shares to compensate the lender. On July 1, 2016, the note was modified to increase the principal amount to $200,000 and we received the remaining proceeds of $85,000 on the same date and issued 34,333 common shares as compensation to the lender. The lender has the right to convert the note into shares of the Company’s common stock at fixed conversion price equal to $0.45 per share, subject to applicable adjustments. We valued the total 65,000 common shares using the stock prices at the respective dates the note proceeds were received and recorded the relative fair value of the shares amounting to $26,000 as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financing. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. On July 29, 2016, we sold an additional convertible note for $100,000 and issued 32,500 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair values of the convertible note and the common shares was $87,241 and $12,759, respectively. We then computed the effective conversion price of the note, noting that the convertible debt gave rise to a beneficial conversion feature (BCF) of $12,759. The sum of the relative fair value of the common shares and the BCF of $25,518 was recorded as a debt discount to be amortized over the term of the loan. We also evaluated the convertible note for derivative liability treatment and determined that the instruments does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangements did not qualify for derivative accounting treatment. On September 15, 2016, we sold an additional convertible note for $500,000 and issued 200,000 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $0.45 per share, subject to applicable adjustments. The convertible note includes an original issue discount of $40,541 and is subject to annual interest of 9%. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair value of the convertible note was $434,028. The allocation of the gross proceeds to the shares of common stock was $65,972 and recorded as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. The specific terms of the convertible debts and outstanding balances as of September 30, 2016 are listed in the table below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % 2 $ 388,532 $ 2,163,074 September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 January 11, 2016 24 months 100,000 100,000 10,000 1 10 % 2 24,966 80,034 January 20, 2016 24 months 50,000 50,000 5,000 1 10 % 2 9,812 40,188 January 29, 2016 24 months 300,000 300,000 30,000 1 10 % 2 60,887 239,113 February 26, 2016 24 months 200,000 200,000 20,000 1 10 % 2 43,952 156,048 March 10, 2016 24 months 125,000 125,000 12,500 1 10 % 2 18,260 106,740 March 18, 2016 24 months 360,000 360,000 36,000 1 10 % 2 94,992 265,008 March 24, 2016 24 months 106,667 106,667 10,667 1 10 % 2 15,427 91,240 March 31, 2016 24 months 167,882 167,882 16,788 1 10 % 2 2,436 165,446 April 5, 2016 24 months 10,000 10,000 1,000 1 10 % 2 - 10,000 May 24, 2016 7 months 100,000 100,000 7,000 0 % - 20,368 June 15, 2016 6 months 40,000 40,000 - 12 % - 3,680 June 17, 2016 6 months 40,000 40,000 - 12 % - 3,899 June 22, 2016 6 months 35,000 35,000 - 12 % - 3,373 July 6, 2016 6 months 85,000 85,000 - 12 % - 15,048 July 29, 2016 6 months 100,000 100,000 - 12 % - 25,518 September 15, 2016 8 months 500,000 500,000 40,541 9 % - 65,972 $ 7,229,549 $ 7,229,549 $ 680,496 $ 1,158,408 $ 6,060,837 1 The original issue discount is reflected in the first year. 2 The annual interest starts accruing in the second year. The closings above on March 10, 24, and 31, 2016 included $264,667 of proceeds received from related parties. At any time after six months from the Inception Date, the Company has the right to prepay the above Debentures in cash for 120% of the principal amount outstanding and any accrued interest. As of September 30, 2016, a total of approximately $291,000 convertible debentures were purchased by related parties who were members of the Company’s Board of Directors. The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2016: 2016 Balance at January 1, $ 277,342 Issuance of convertible debt, face value 2,509,045 Original issue discount (189,496 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (1,153,817 ) Debt discount from shares and warrants issued with the notes (117,137 ) Debt discount from beneficial conversion feature (20,721 ) Deferred financing fees (270,732 ) Conversion of debentures to common shares (100,000) Accretion of interest and amortization of debt discount to interest expense through September 30, 2,808,261 Balance at September 30, 3,742,745 Less: current portion 2,664,334 Convertible debt, long-term portion $ 1,078,411 Other Notes On January 6, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $250,000 in exchange for rights to all customer receipts until the lender is paid $322,500, which is collected at the rate of $1,280 per business day. The payments were secured by second position rights to all customer receipts until the loan has been paid in full. $138,840 of the proceeds were used to pay off the outstanding balance of a previous loan from another lender. The Company recognized a gain on the settlement of the previous loan of $5,044 which was credited to interest expense. The Company paid $2,500 in fees in connection with this loan. We received an additional $93,161 in June 2016 under the existing Merchant Agreement. The note was still outstanding as of September 30, 2016 with a balance of $105,125. On January 20, 2016, we borrowed $50,000 from an individual with no interest or fees. We paid back the loan in March 2016. On February 8, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $100,000 in exchange for third position rights to all customer receipts until the lender is paid $129,900, which is collected at the rate of $927 per business day. The Company paid $2,000 in fees in connection with this loan. We received an additional $125,000 in June 2016 under the existing Merchant Agreement of which $48,420 was used to pay off the prior loan. The note was still outstanding as of September 30, 2016 with a balance of $4,620 after payments of $56,841. The lender provided an additional $70,000 on August 16, 2016. We repaid a portion of the $70,000 with $49,200 remaining as outstanding as of September 30, 2016. On May 9, 2016 we signed a promissory note with a lender. Under the agreement we received $200,000 net of a $6,000 original issue discount and we repaid $206,000 on August 25, 2016. In connection with this promissory note, we issued warrants exercisable into 100,000 shares of our common stock. The warrants issued in this transaction are immediately exercisable at an exercise price of $0.55 per share. The warrants have an expiration period of three years from the original issue date. The warrants are subject to adjustment for stock splits, stock dividends or recapitalizations. The warrants were recorded as a component of our Stockholders’ Equity. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $27,349 to the total warrants and recorded as a discount to the note to be amortized over the term of the loan. We evaluated the warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that these instruments did not qualify for derivative accounting treatment. In August, 2016, the lender extended the maturity date of the note from August 11, 2016 to August 25, 2016. Consequently, a penalty interest of $41,200 was added to the principal amount and settled through the issuance of 100,049 common shares. As of September 30, 2016, the outstanding balance on this note was zero. On August 26, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $122,465 net proceeds in exchange for rights to all customer receipts which is collected at the rate of $1,386 per business day. The note was still outstanding as of September 30, 2016 with a balance of $89,201.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Deficit	7) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K As of September 30, 2016, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2015 for the pertinent disclosures of preferred stock. Stock Options and Warrants Our stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016, options to acquire 1,153,750 shares were outstanding under the Plan with 646,250 shares available for future grant under the Plan. On December 12, 2013 at the Company’s special meeting the shareholders approved the 2013 Equity Incentive Plan (the “2013 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Under the 2013 Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016 a total of 2,047,500 options have been granted under the 2013 Plan with 952,500 shares available for future grants. On November 29, 2015 the Company’s Board of Directors adopted the 2015 Nonqualified Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of our common stock were reserved for issuance upon exercise of non-qualified stock options. Under the 2015 Plan, we may award non-qualified stock options in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016, non-qualified options to acquire 2,068,000 shares were outstanding under the Plan with 2,932,000 shares available for future grants under the 2015 Plan. All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price on September 30, 2016. The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Total Shares Price per share Shares Price per share Shares Exercisable Balance outstanding, 01/01/15 3,406,250 $ 0.51 19,182,201 $ 0.49 22,588,451 16,611,528 Granted 2,500,000 0.40 10,837,141 0.40 13,337,141 Exercised — — — — Expired (205,000 ) 1.00 (791,678 ) 0.31 (996,678 ) Forfeited (130,000 ) 0.70 — — (130,000 ) Balance outstanding, 12/31/15 5,571,250 $ 0.44 29,227,664 $ 0.44 34,798,914 31,664,469 Granted — — 4,294,552 0.43 4,294,552 Exercised — (70,000 ) 0.31 (70,000 ) Expired (186,000 ) 1.00 (8,627,521 ) 0.61 (8,813,521 ) Forfeited (116,000 ) 0.51 — — (116,000 ) Balance outstanding, 9/30/2016 5,269,250 $ 0.42 24,824,695 $ 0.39 30,093,945 28,095,959 Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,625,500 8.0 $ 0.30 1,248,514 8.0 $ 0.30 0.40 - 0.49 2,786,000 9.0 0.40 1,165,000 8.6 0.40 0.50 - 0.59 226,250 5.9 0.50 226,250 5.9 0.50 0.60 - 0.69 385,500 3.4 0.60 385,500 3.4 0.60 0.70 - 1.25 246,000 2.6 1.00 246,000 2.6 1.00 $0.30 - $1.25 5,269,250 7.8 $ 0.42 3,271,264 7.1 $ 0.44 As of September 30, 2016, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $459,724. The non-cash, stock-based compensation expense associated with the vesting of these options is expected to be $90,445 for the remainder of 2016, $212,957 in 2017 and $156,322 in 2018. Common Stock Issuances On April 22, 2016, we issued 22,996 shares of common stock in connection with a cashless exercise of 70,000 warrants. On May 6, 2016, all remaining Series K preferred shareholders except one converted 4,600 shares of preferred stock into approximately 4.6 million shares of the Company’s common stock. The Company issued 247,435 shares of common stock to pay the accrued dividend of $63,413 on Series K preferred stock. On May 13, 2016, we issued 420,849 shares of common stock to convert $117,837 of convertible note principal and related interest. See Note 6 On various dates from January to September 2016, we issued a total of 297,500 shares of common stock in connection with the convertible notes issued to lenders. We also issued 100,049 shares of common stock to settle debt of $41,200. See Note 6. On August 29, 2016, a Series J preferred shareholder converted 25 shares of preferred stock into 25,000 shares of the Company’s common stock. The Company issued 1,112 shares of common stock to pay the accrued dividend of $445 on Series J preferred stock. On various dates from January to September 2016 the Company issued 755,000 shares of restricted common stock to investor relations firms for services rendered. Sale of Common Stock On August 29, September 9 and September 14, 2016, we completed private placements, pursuant to which we sold an aggregate of 1,125,000 shares of common stock, $0.01 par value, for a purchase price of $0.40 per share, resulting in gross proceeds to us of approximately $450,000. The shares were issued and sold to a total of 2 accredited investors pursuant to a securities purchase agreement entered into as of August 29, 2016. The investors received warrants to purchase 1,125,000 shares of the Company’s common stock at $0.50 exercise price. The warrants expire 5 years after issuance. We also incurred stock issuance costs related to broker and legal fees of $67,035 which were charged to additional paid in capital.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	8) Subsequent Events On October 11 and November 10, 2016, we completed two additional tranches of the Fall 2016 Private Placement, pursuant to which we sold an aggregate of 400,000 shares of common stock, $0.01 par value, for a purchase price of $0.40 per share, resulting in gross proceeds to us of approximately $160,000. The Shares were issued and sold to a total of 2 accredited investors pursuant to a Securities Purchase Agreement entered into as of the date of their investments. The investors received warrants to purchase a total of 400,000 shares of the Company’s common stock at an exercise price of $0.50. The warrants expire 5 years after issuance. On October 28, 2016, an accredited investor (the “Investor”) purchased a promissory note in the aggregate principal amount of up to $2,000,000 (the “Note”) due and payable on the earlier of October 28, 2017 or on the seventh business day after the closing of a Qualified Offering (as defined in the Note). Although the Note is dated October 26, 2016, the transaction did not close until October 28, 2016, when the Company received its initial $250,000 advance pursuant to the Note. As a result, on the same day and pursuant to the Note, the Company issued to the Investor a Common Stock Purchase Warrant to purchase 625,000 shares of the Company’s common stock (“Common Stock”) at an exercise price per share equal to $0.40 per share. The Investor is obligated to provide the Company $250,000 advances under the Note, but the Investor shall not be required to advance more than $250,000 in any individual fifteen (15) day period and no more than $500,000 in the thirty (30) day period immediately following the date of the initial advance. Notwithstanding the fifteen (15) day period limitation, on November 2, 2016, the Company received a second $250,000 advance pursuant to the Note and the Company issued to the Investor the second warrant to purchase 625,000 shares of the Common Stock. The terms of the first and second warrants are identical except for the exercise date, issue date, and termination date. Interest on the principal balance of the Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. Interest shall be assessed as follows: (i) 10% on all principal amounts advanced prior to April 28, 2017; (ii) the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between April 28, 2017 and July28, 2017; or (iii) both of the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between July 28, 2017 and October 28, 2017. Our placement agent is being paid eight percent (8%) of all principal amounts advanced in connection with this transaction. On November 1, 2016, we signed a consulting agreement with an investor relations firm for a twelve month period with a six-month cancellation clause. In connection with this agreement, we issued a warrant exercisable at $0.40 per share for 660,000 shares of our common stock. Of these shares, 330,000 vest immediately and 330,000 shares vest 181 days after November 1, 2016. The warrant expires five years from issuance.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications	Reclassifications Certain amounts in the 2015 consolidated financial statements have been reclassified to conform to the 2016 presentation.
Use of Estimates	Use of Estimates To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2016 and 2015. For the Three Months Ended September 30, 2016 2015 Top Five Customers 60 % 43 % Federal Agencies 9 % 2 % For the Nine Months Ended September 30, 2016 2015 Top Five Customers 31 % 34 % Federal Agencies 3 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2016 and December 31, 2015: September 30, 2016 December, 31, 2015 Top Five Customers 55 % 93 % Federal Agencies 9 % 1 %
Product Supply	Product Supply A Massachusetts-based contract manufacturer started building the new NEP2320 Extreme Barocycler instrument in May 2016. We plan to have this manufacturer build all instruments in the future.
Investment in Available-For-Sale Equity Securities	Investment in Available-For-Sale Equity Securities As of September 30, 2016, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Inventories	Inventories Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory is as follows: September 30, 2016 December 31, 2015 Raw materials $ 491,254 $ 310,367 Finished goods 566,884 778,004 Inventory Reserve (50,000 ) (50,000 ) Total $ 1,008,138 $ 1,038,371
Debt Issuance Costs	Debt Issuance Costs In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively.
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2016 and 2015: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Numerator: Net loss $ (945,207 ) $ (657,928 ) $ (5,933,768 ) $ (3,430,160 ) Preferred dividends accrued — 1,711 — (21,768 ) Net loss applicable to common shareholders $ (945,207 ) $ (656,217 ) $ (5,933,768 ) $ (3,451,928 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 29,425,362 20,737,827 26,139,740 19,771,323 Income (loss) per common share – basic and diluted $ (0.03 ) $ (0.03 ) $ (0.23 ) $ (0.17 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of September 30, 2016 2015 Stock options 5,269,250 3,201,250 Convertible debt 26,971,732 26,015,029 Common stock warrants 24,888,980 26,125,127 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 2,100,000 Series J Convertible Preferred Stock 3,521,000 3,546,000 Series K Convertible Preferred Stock 6,816,000 11,399,000 72,182,662 75,002,106
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining Fair Value of Stock Option Grants	Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $90,500 and $74,864 for the three months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2016 2015 Research and development $ 14,735 $ 18,307 Selling and marketing 9,911 13,310 General and administrative 65,854 43,247 Total stock-based compensation expense $ 90,500 $ 74,864 The Company recognized stock-based compensation expense of $282,811 and $185,370 for the nine months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30 2016 2015 Research and development $ 50,766 $ 41,172 Selling and marketing 32,404 27,386 General and administrative 199,641 116,812 Total stock-based compensation expense $ 282,811 $ 185,370
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue with carrying values that approximate fair value.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2016: Fair value measurements at September 30, 2016 using: September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 59,550 $ 59,550 $ 0 $ - Total Financial Assets $ 59,550 $ 59,550 $ — $ - September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 189,884 — — $ 189,884 Warrants Issued with Convertible Debt 4,135,980 — — 4,135,980 Conversion Option Derivative Liabilities 4,627,452 — — 4,627,452 Total Derivatives $ 8,953,316 $ — $ — $ 8,953,316 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the nine months ended September 30, 2016: December 31,2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2016 Available-For-Sale Equity Securities $ 294,522 - $ (234,972 ) $ — $ 59,550 Total Financial Assets $ 294,522 $ — $ (234,972 ) $ — $ 59,550 December 31, 2015 Issuance fair value Change in fair value September 30, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ — $ 16,358 $ 189,884 Convertible Debt Warrants 3,122,450 1,094,432 (80,902 ) 4,135,980 Conversion Option Liabilities 3,940,791 1,547,127 (860,466 ) 4,627,452 Total Derivatives $ 7,236,767 $ 2,641,559 $ (925,010 ) $ 8,953,316 The amounts above valued at issuance includes $1,337,510 that was charged directly to “change in fair value of derivative liabilities” at issuance. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015: Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 294,522 $ 294,522 $ — $ — Total Financial Assets $ 294,522 $ 294,522 $ — $ — December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 — — $ 173,526 Warrants Issued with Convertible Debt 3,122,450 — — 3,122,450 Conversion Option Derivative Liabilities 3,940,791 — — 3,940,791 Total Derivatives $ 7,236,767 $ — $ — $ 7,236,767 The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 60.0 11.0 8.0 Expected volatility 104.5 % 104.9 % 92.4 % Risk-free interest rate 0.875 % 0.65 % 0.45 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.18 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the period reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 36.0-60.0 55.0-60.0 46.0-54.0 Expected volatility 114.3 - 138.3 % 136.3-141.6 % 116.2 -137.4 % Risk-free interest rate 0.86-1.69 % 1.29-1.76 % 1.01 % Exercise price $ 0.40-0.42 0.40 $ 0.40 Fair value per warrant $ 0.19-$.40 0.30 $ 0.30-$1.35 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2015 Conversion options revalued at September 30, 2016 Expected life (in months) 3-24 18-24 10-18 Expected volatility 97.6-153.8 % 112.2-114.7 % 94.3%-96.6 % Risk-free interest rate 0.37-0.99 % 1.06 % 0.59-0.77 % Exercise price $ 0.24-$0.45 $ 0.28 $ 0.28 Fair value per conversion option $ 0.07-$0.30 $ 0.14-$0.33 $ 0.17-$0.21

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2016 and 2015. For the Three Months Ended September 30, 2016 2015 Top Five Customers 60 % 43 % Federal Agencies 9 % 2 % For the Nine Months Ended September 30, 2016 2015 Top Five Customers 31 % 34 % Federal Agencies 3 % 14 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2016 and December 31, 2015: September 30, 2016 December, 31, 2015 Top Five Customers 55 % 93 % Federal Agencies 9 % 1 %
Schedule of Inventories	The composition of inventory is as follows: September 30, 2016 December 31, 2015 Raw materials $ 491,254 $ 310,367 Finished goods 566,884 778,004 Inventory Reserve (50,000 ) (50,000 ) Total $ 1,008,138 $ 1,038,371
Summary of Computation of Loss per Share	The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2016 and 2015: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Numerator: Net loss $ (945,207 ) $ (657,928 ) $ (5,933,768 ) $ (3,430,160 ) Preferred dividends accrued — 1,711 — (21,768 ) Net loss applicable to common shareholders $ (945,207 ) $ (656,217 ) $ (5,933,768 ) $ (3,451,928 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 29,425,362 20,737,827 26,139,740 19,771,323 Income (loss) per common share – basic and diluted $ (0.03 ) $ (0.03 ) $ (0.23 ) $ (0.17 )
Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of September 30, 2016 2015 Stock options 5,269,250 3,201,250 Convertible debt 26,971,732 26,015,029 Common stock warrants 24,824,695 26,125,127 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 2,100,000 Series J Convertible Preferred Stock 3,521,000 3,546,000 Series K Convertible Preferred Stock 6,816,000 11,399,000 72,118,377 75,002,106
Summary of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2016 2015 Research and development $ 14,735 $ 18,307 Selling and marketing 9,911 13,310 General and administrative 65,854 43,247 Total stock-based compensation expense $ 90,500 $ 74,864 The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30 2016 2015 Research and development $ 50,766 $ 41,172 Selling and marketing 32,404 27,386 General and administrative 199,641 116,812 Total stock-based compensation expense $ 282,811 $ 185,370
Schedule of Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2016: Fair value measurements at September 30, 2016 using: September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 59,550 $ 59,550 $ - $ - Total Financial Assets $ 59,550 $ 59,550 $ - $ - September 30, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 189,884 $ — $ — $ 189,884 Warrants Issued with Convertible Debt 4,135,980 — — 4,135,980 Conversion Option Derivative Liabilities 4,627,452 — — 4,627,452 Total Derivatives $ 8,953,316 $ — $ — $ 8,953,316 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the nine months ended September 30, 2016: December 31,2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2016 Available-For-Sale Equity Securities $ 294,522 $ - $ (234,972 ) $ — $ 59,550 Total Financial Assets $ 294,522 $ — $ (234,972 ) $ — $ 59,550 December 31, 2015 Issuance fair value Change in fair value September 30, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ — $ 16,358 $ 189,884 Convertible Debt Warrants 3,122,450 1,094,432 (80,902 ) 4,135,980 Conversion Option Liabilities 3,940,791 1,547,127 (860,466 ) 4,627,452 Total Derivatives $ 7,236,767 $ 2,641,559 $ (925,010 ) $ 8,953,316 The amounts above valued at issuance includes $1,337,510 that was charged directly to “change in fair value of derivative liabilities” at issuance. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015: Fair value measurements at December 31, 2015 using: December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities $ 294,522 $ 294,522 $ — $ — Total Financial Assets $ 294,522 $ 294,522 $ — $ — December 31, 2015 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 173,526 $ — $ — $ 173,526 Warrants Issued with Convertible Debt 3,122,450 — — 3,122,450 Conversion Option Derivative Liabilities 3,940,791 — — 3,940,791 Total Derivatives $ 7,236,767 $ — $ — $ 7,236,767
Schedule of Fair Value Assumptions	The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 60.0 11.0 8.0 Expected volatility 104.5 % 104.9 % 92.4 % Risk-free interest rate 0.875 % 0.65 % 0.45 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.16 $ 0.18 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the period reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2015 Warrants revalued at September 30, 2016 Expected life (in months) 36.0-60.0 55.0-60.0 46.0-54.0 Expected volatility 114.3 - 138.3 % 136.3-141.6 % 116.2 -137.4 % Risk-free interest rate 0.86-1.69 % 1.29-1.76 % 1.01 % Exercise price $ 0.40-0.42 0.40 $ 0.40 Fair value per warrant $ 0.19-$.40 0.30 $ 0.30-$1.35 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value Conversion options revalued at December 31, 2015 Conversion options revalued at September 30, 2016 Expected life (in months) 3-24 18-24 10-18 Expected volatility 97.6-153.8 % 112.2-114.7 % 94.3%-96.6 % Risk-free interest rate 0.37-0.99 % 1.06 % 0.59-0.77 % Exercise price $ 0.24-$0.45 $ 0.28 $ 0.28 Fair value per conversion option $ 0.07-$0.30 $ 0.14-$0.33 $ 0.17-$0.21

Convertible Debt and Other De17

Convertible Debt and Other Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible debts and outstanding balances as of September 30, 2016 are listed in the table below. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $ 218,000 1 10 % 2 $ 388,532 $ 2,163,074 September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 1,022,052 October 2, 2015 24 months 150,000 150,000 15,000 1 10 % 2 26,345 140,832 October 6, 2015 24 months 30,000 30,000 3,000 1 10 % 2 5,168 26,721 October 14, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,954 49,377 November 2, 2015 24 months 250,000 250,000 25,000 1 10 % 2 43,079 222,723 November 10, 2015 24 months 50,000 50,000 5,000 1 10 % 2 8,790 46,984 November 12, 2015 24 months 215,000 215,000 21,500 1 10 % 2 38,518 212,399 November 20, 2015 24 months 200,000 200,000 20,000 1 10 % 2 37,185 200,000 December 4, 2015 24 months 170,000 170,000 17,000 1 10 % 2 37,352 170,000 December 11, 2015 24 months 360,000 360,000 36,000 1 10 % 2 75,449 360,000 December 18, 2015 24 months 55,000 55,000 5,500 1 10 % 2 11,714 55,000 December 31, 2015 24 months 100,000 100,000 10,000 1 10 % 2 20,634 100,000 January 11, 2016 24 months 100,000 100,000 10,000 1 10 % 2 24,966 80,034 January 20, 2016 24 months 50,000 50,000 5,000 1 10 % 2 9,812 40,188 January 29, 2016 24 months 300,000 300,000 30,000 1 10 % 2 60,887 239,113 February 26, 2016 24 months 200,000 200,000 20,000 1 10 % 2 43,952 156,048 March 10, 2016 24 months 125,000 125,000 12,500 1 10 % 2 18,260 106,740 March 18, 2016 24 months 360,000 360,000 36,000 1 10 % 2 94,992 265,008 March 24, 2016 24 months 106,667 106,667 10,667 1 10 % 2 15,427 91,240 March 31, 2016 24 months 167,882 167,882 16,788 1 10 % 2 2,436 165,446 April 5, 2016 24 months 10,000 10,000 1,000 1 10 % 2 - 10,000 May 24, 2016 7 months 100,000 100,000 7,000 0 % - 20,368 June 15, 2016 6 months 40,000 40,000 - 12 % - 3,680 June 17, 2016 6 months 40,000 40,000 - 12 % - 3,899 June 22, 2016 6 months 35,000 35,000 - 12 % - 3,373 July 6, 2016 6 months 85,000 85,000 - 12 % - 15,048 July 29, 2016 6 months 100,000 100,000 - 12 % - 25,518 September 15, 2016 8 months 500,000 500,000 40,541 9 % - 65,972 $ 7,229,549 $ 7,229,549 $ 680,496 $ 1,158,408 $ 6,060,837
Summary of Changes in Convertible Debt, Net of Unamortized Discount	The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2016: 2016 Balance at January 1, $ 277,342 Issuance of convertible debt, face value 2,509,045 Original issue discount (189,496 ) Debt discount from derivative liabilities (embedded conversion option and warrants) (1,153,817 ) Debt discount from shares and warrants issued with the notes (117,137 ) Debt discount from beneficial conversion feature (20,721 ) Deferred financing fees (270,732 ) Conversion of debentures to common shares (100,000) Accretion of interest and amortization of debt discount to interest expense through September 30, 2,808,261 Balance at September 30, 3,742,745 Less: current portion 2,664,334 Convertible debt, long-term portion $ 1,078,411

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Total Shares Price per share Shares Price per share Shares Exercisable Balance outstanding, 01/01/15 3,406,250 $ 0.51 19,182,201 $ 0.49 22,588,451 16,611,528 Granted 2,500,000 0.40 10,837,141 0.40 13,337,141 Exercised — — — — Expired (205,000 ) 1.00 (791,678 ) 0.31 (996,678 ) Forfeited (130,000 ) 0.70 — — (130,000 ) Balance outstanding, 12/31/15 5,571,250 $ 0.44 29,227,664 $ 0.44 34,798,914 31,664,469 Granted — — 4,294,552 0.43 4,294,552 Exercised — (70,000 ) 0.31 (70,000 ) Expired (186,000 ) 1.00 (8,627,521 ) 0.61 (8,813,521 ) Forfeited (116,000 ) 0.51 — — (116,000 ) Balance outstanding, 9/30/2016 5,269,250 $ 0.42 24,824,695 $ 0.39 30,093,945 28,095,959
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,625,500 8.0 $ 0.30 1,248,514 8.0 $ 0.30 0.40 - 0.49 2,786,000 9.0 0.40 1,165,000 8.6 0.40 0.50 - 0.59 226,250 5.9 0.50 226,250 5.9 0.50 0.60 - 0.69 385,500 3.4 0.60 385,500 3.4 0.60 0.70 - 1.25 246,000 2.6 1.00 246,000 2.6 1.00 $0.30 - $1.25 5,269,250 7.8 $ 0.42 3,271,264 7.1 $ 0.44

Business Overview, Liquidity 19

Business Overview, Liquidity and Management Plans (Details Narrative)	9 Months Ended
	Sep. 30, 2016lb
Pounds per square inch	35,000
PBI Europe [Member]
Percentage of ownership interest	49.00%
Investment Bank [Member]
Percentage of ownership interest	51.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2016	Sep. 30, 2016
Going Concern
Over subscribed on debt financing	$ 5,000,000
Debt financing	$ 6,300,000
Net proceeds from additional convertible and non-convertible debt		$ 3,447,166

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Forfeiture rate percentage			5.00%
Stock-based compensation expense	$ 90,500	$ 74,864	$ 282,811	$ 185,370
Change in fair value of derivative liabilities			$ 1,337,510
Everest Investments Holding [Member]
Sale of stock number of shares recevied			601,500
Fair value of investment	$ 59,550		$ 59,550
Shares closing price per share	$ 0.10		$ 0.10

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Summary of Customer Concentration Risk Percentage (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Top Five Customers [Member] | Revenue [Member]
Concentration as a percentage	60.00%	43.00%	31.00%	34.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration as a percentage			55.00%		93.00%
Federal Agencies [Member] | Revenue [Member]
Concentration as a percentage	9.00%	2.00%	3.00%	14.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration as a percentage			9.00%		1.00%

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies - Schedule Of Inventories Details
Raw materials	$ 491,254	$ 310,367
Finished goods	566,884	778,004
Inventory Reserve	(50,000)	(50,000)
Total	$ 1,008,138	$ 1,038,371

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Summary of Computation of Loss per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accounting Policies [Abstract]
Net loss	$ (945,207)	$ (657,928)	$ (5,933,768)	$ (3,430,160)
Preferred dividends accrued		1,711		(21,768)
Net loss applicable to common shareholders	$ (945,207)	$ (656,217)	$ (5,933,768)	$ (3,451,928)
Weighted average common stock shares outstanding	29,425,362	20,737,827	26,139,740	19,771,323
Income (loss) per common share - basic and diluted	$ (0.03)	$ (0.03)	$ (0.23)	$ (0.17)

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Total potentially dilutive shares	5,269,250	3,201,250
Convertible Debt [Member]
Total potentially dilutive shares	26,971,732	26,015,029
Common Stock Warrants [Member]
Total potentially dilutive shares	24,824,695	26,125,127
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	750,000	750,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	865,700	865,700
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	1,000,000	1,000,000
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	2,100,000	2,100,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	3,521,000	3,546,000
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	6,816,000	11,399,000
Potentially Dilutive Shares [Member]
Total potentially dilutive shares	72,118,377	75,002,106

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Summary of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Total stock-based compensation expense	$ 90,500	$ 74,864	$ 282,811	$ 185,370
Research and Development [Member]
Total stock-based compensation expense	14,735	18,307	50,766	41,172
Selling and Marketing [Member]
Total stock-based compensation expense	9,911	13,310	32,404	27,386
General and Administrative [Member]
Total stock-based compensation expense	$ 65,854	$ 43,247	$ 199,641	$ 116,812

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Total Financial Assets	$ 59,550		$ 59,550		$ 294,522
Fair value of derivative liability	8,953,316		8,953,316		7,236,767
Balance			7,236,767
Issuance fair value			2,641,559
Change in Fair Value			(925,010)
Gain on extinguishment of derivative liabilities	623,128	$ 437,379	(412,500)	$ 38,968
Balance	8,953,316		8,953,316
Financial Assets [Member]
Balance			294,522
Issuance fair value
Change in Fair Value			(234,972)
Gain on extinguishment of derivative liabilities
Balance	59,550		59,550
Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	59,550		59,550		294,522
Fair value of derivative liability
Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets	0		0
Fair value of derivative liability
Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets	0		0
Fair value of derivative liability	8,953,316		8,953,316		7,236,767
Available-For-Sale Equity Securities [Member]
Total Financial Assets	59,550		59,550		294,522
Balance			294,522
Balance	59,550		59,550
Available-For-Sale Equity Securities [Member] | Financial Assets [Member]
Balance			294,522
Issuance fair value
Change in Fair Value			(234,972)
Gain on extinguishment of derivative liabilities
Balance	59,550		59,550
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	59,550		59,550		294,522
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Series D Preferred Stock Purchase Warrants [Member]
Fair value of derivative liability	189,884		189,884		173,526
Balance			173,526
Issuance fair value
Change in Fair Value			16,358
Balance	189,884		189,884
Series D Preferred Stock Purchase Warrants [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	189,884		189,884		173,526
Warrants Issued with Convertible Debt [Member]
Fair value of derivative liability	4,135,980		4,135,980		3,122,450
Balance			3,122,450
Balance	4,135,980		4,135,980
Warrants Issued with Convertible Debt [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	4,135,980		4,135,980		3,122,450
Conversion Option Derivative Liabilities [Member]
Fair value of derivative liability	4,627,452		4,627,452		3,940,791
Balance			3,940,791
Balance	4,627,452		4,627,452
Conversion Option Derivative Liabilities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	4,627,452		4,627,452		$ 3,940,791
Convertible Debt Warrants [Member]
Balance			3,122,450
Issuance fair value			1,094,432
Change in Fair Value			(80,902)
Balance	4,135,980		4,135,980
Conversion Option Liabilities [Member]
Balance			3,940,791
Issuance fair value			1,547,127
Change in Fair Value			(860,466)
Balance	$ 4,627,452		$ 4,627,452

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Fair Value Assumptions (Details) - $ / shares	Nov. 10, 2011	Sep. 30, 2016	Dec. 31, 2015
Expected life (in months)	60 months
Expected volatility	104.50%
Risk-free interest rate	0.875%
Exercise price	$ 0.81
Fair value per share	$ 0.54
Warrants Issued with Convertible Debt [Member] | Warrants Revalued at December 31, 2015 [Member]
Exercise price			$ 0.40
Fair value per share			$ 0.30
Warrants Revalued at December 31, 2015 [Member]
Expected life (in months)			11 months
Expected volatility			104.90%
Risk-free interest rate			0.65%
Exercise price			$ .25
Fair value per share			$ 0.16
Warrants Revalued at December 31, 2015 [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)			55 months
Expected volatility			136.30%
Risk-free interest rate			1.29%
Warrants Revalued at December 31, 2015 [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)			60 months
Expected volatility			141.60%
Risk-free interest rate			1.76%
Warrants Revalued at September 30, 2016 [Member]
Expected life (in months)		8 months
Expected volatility		92.40%
Risk-free interest rate		0.45%
Exercise price		$ 0.25
Fair value per share		$ 0.18
Warrants Revalued at September 30, 2016 [Member] | Warrants Issued with Convertible Debt [Member]
Risk-free interest rate		1.01%
Exercise price		$ 0.40
Warrants Revalued at September 30, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)		46 months
Expected volatility		116.20%
Fair value per share		$ 0.30
Warrants Revalued at September 30, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)		54 months
Expected volatility		137.40%
Fair value per share		$ 1.35
Issuance Fair Value [Member] | Minimum [Member]
Expected life (in months)		3 months
Expected volatility		97.60%
Risk-free interest rate		0.37%
Exercise price		$ 0.24
Fair value per share		$ 0.07
Issuance Fair Value [Member] | Maximum [Member]
Expected life (in months)		24 months
Expected volatility		153.80%
Risk-free interest rate		0.99%
Exercise price		$ 0.45
Fair value per share		$ 0.30
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)		36 months
Expected volatility		114.30%
Risk-free interest rate		0.86%
Exercise price		$ 0.40
Fair value per share		$ 0.19
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)		60 months
Expected volatility		138.30%
Risk-free interest rate		1.69%
Exercise price		$ 0.42
Fair value per share		0.40
Conversion Options Revalued at December 31, 2015 [Member]
Risk-free interest rate			1.06%
Exercise price			$ 0.28
Conversion Options Revalued at December 31, 2015 [Member] | Minimum [Member]
Expected life (in months)			18 months
Expected volatility			112.20%
Fair value per share			$ 0.14
Conversion Options Revalued at December 31, 2015 [Member] | Maximum [Member]
Expected life (in months)			24 months
Expected volatility			114.70%
Fair value per share			$ 0.33
Conversion Options Revalued at September 30, 2016 [Member]
Exercise price		$ 0.28
Conversion Options Revalued at September 30, 2016 [Member] | Minimum [Member]
Expected life (in months)		10 months
Expected volatility		94.30%
Risk-free interest rate		0.59%
Fair value per share		$ 0.17
Conversion Options Revalued at September 30, 2016 [Member] | Maximum [Member]
Expected life (in months)		18 months
Expected volatility		96.60%
Risk-free interest rate		0.77%
Fair value per share		$ 0.21

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 29, 2015	Nov. 01, 2014	Sep. 30, 2016	Sep. 30, 2015
Rental expenses		$ 5,385	$ 108,038	$ 73,775
Extended lease term		Dec. 30, 2017
Grand received			$ 1,050,000
Corporate Office [Member]
Rental expenses	$ 4,800
Extended lease term	Dec. 31, 2016

Convertible Debt and Other De30

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Sep. 15, 2016	Aug. 26, 2016	Aug. 25, 2016	Jul. 29, 2016	Jul. 02, 2016	Jun. 14, 2016	May 24, 2016	May 13, 2016	Feb. 08, 2016	Jan. 20, 2016	Jun. 06, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 16, 2016	Jun. 30, 2016	May 09, 2016	Dec. 31, 2015	Jan. 06, 2014
Warrants purchase price												$ 5,683,897					$ 5,416,681
Debt principal amount												$ 2,509,045
Percentage of outstanding principal amount of debenture												120.00%
Warrants rights description												Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTC QB Market (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days.
Amortized of debt discount												$ 2,768,527
Fair value of warrant												2,847,624
Gross proceeds from warrants												6,329,549
Debt conversion amount								$ 117,837				(100,000)
Debt conversion into common stock shares								420,849
Beneficial conversion feature												(20,721)
Proceeds from pay off outstanding balance of previous loan												264,667
Proceeds from common stock												382,965
Convertible debentures issued to related parties												291,000
Borrowed from related parties												96,667	6,300
Repayment of debt													$ 2,107,065
Gain on settlement of previous loan												5,044
Other Convertible Notes [Member]
Debt principal amount					$ 200,000
Percentage of annual interest rates	9.00%
Debt conversion price per share	$ 0.45			$ 0.45	$ 0.45		$ 0.45
Issuance of warrants to purchase of common stock shares							50,000
Warrant exercise price per share							$ .55
Amortized of debt discount	$ 40,541			$ 25,518	$ 26,000
Fair value of warrant							$ 12,406
Debt conversion into common stock shares	200,000			32,500	65,000	30,667
Additional convertible debentures	$ 500,000			$ 100,000		$ 115,000	107,000
Beneficial conversion feature				12,759			$ 7,962
Proceeds from pay off outstanding balance of previous loan					$ 85,000
Fair value of convertible note	434,028			87,241
Fair value of common shares				$ 12,759
Proceeds from common stock	$ 65,972
Individuals [Member]
Borrowed from related parties										$ 50,000
Lender [Member]
Debt conversion amount												$ 41,200
Debt conversion into common stock shares												100,049
Lender [Member] | Merchant Agreement [Member]
Debt principal amount									$ 100,000					$ 70,000	$ 125,000
Other note outstanding balance												$ 4,620
Other note outstanding balance after payment												56,841
Proceeds from pay off outstanding balance of previous loan		$ 122,645
Fair value of convertible note												49,200
Payment of other notes									129,900
Collected rate business day		$ 1,386							927
Debenture fee									$ 2,000
Pay off prior loan amount															$ 48,420
Repayment of debt												70,000
Lender [Member] | Other Convertible Notes [Member]
Debt conversion amount								$ 117,837
Debt conversion into common stock shares								420,849
Other note outstanding balance												0
Lender [Member] | Other Notes [Member] | Merchant Agreement [Member]
Debt principal amount												93,161						$ 250,000
Other note outstanding balance												105,125
Proceeds from pay off outstanding balance of previous loan											$ 138,840
Payment of other notes											322,500
Collected rate business day											$ 1,280
Debenture fee																		$ 2,500
Lender [Member] | Promissory Note [Member] | Merchant Agreement [Member]
Debt principal amount																$ 200,000
Issuance of warrants to purchase of common stock shares																100,000
Warrant exercise price per share																$ 0.55
Amortized of debt discount			$ 6,000
Fair value of warrant			27,349
Debt conversion amount			$ 41,200
Debt conversion into common stock shares			100,049
Other note outstanding balance												0
Repayment of debt			$ 206,000
Loan paid back date			Aug. 25, 2016
Debt maturity date start			Aug. 11, 2016
Debt maturity date ending			Aug. 25, 2016
Lender [Member] | Merchant Agreement [Member]
Other note outstanding balance												$ 91,736
Subscription Agreement [Member] | Individuals [Member] | July 23, 2015 and March 31, 2016 [Member]
Percentage of warrants to purchase shares of common stock												50.00%
Warrants purchase price												$ 6,329,549
Debt principal amount												$ 6,962,504
Percentage of debt original issue discount on purchase price												10.00%
Percentage of annual interest rates												10.00%
Convertible debentures term												2 years
Debt conversion price per share												$ 0.28
Percentage of outstanding principal amount of debenture												120.00%
Issuance of warrants to purchase of common stock shares												11,302,766
Warrant exercise price per share												$ 0.40
Warrants expiration period												5 years

Convertible Debt and Other De31

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Loan Amount	$ 2,509,045
Discount related to Fair value of conversion feature and warrants/shares	(20,721)
Fixed Rate Convertible Notes [Member]
Loan Amount	7,229,549
Outstanding Balance	7,229,549
Original Issue Discount	680,495
Deferred Finance Fees	1,158,408
Discount related to Fair value of conversion feature and warrants/shares	$ 6,060,837
Fixed Rate Convertible Notes [Member] | Convertible Debt [Member]
Inception Date	Jul. 22, 2015
Term	24 months
Loan Amount	$ 2,180,000
Outstanding Balance	2,180,000
Original Issue Discount	$ 218,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 388,532
Discount related to Fair value of conversion feature and warrants/shares	$ 2,163,074
Fixed Rate Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date	Sep. 25, 2015
Term	24 months
Loan Amount	$ 1,100,000
Outstanding Balance	1,100,000
Original Issue Discount	$ 110,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 185,956
Discount related to Fair value of conversion feature and warrants/shares	$ 1,022,052
Fixed Rate Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date	Oct. 2, 2015
Term	24 months
Loan Amount	$ 150,000
Outstanding Balance	150,000
Original Issue Discount	$ 15,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 26,345
Discount related to Fair value of conversion feature and warrants/shares	$ 140,832
Fixed Rate Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date	Oct. 6, 2015
Term	24 months
Loan Amount	$ 30,000
Outstanding Balance	30,000
Original Issue Discount	$ 3,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 5,168
Discount related to Fair value of conversion feature and warrants/shares	$ 26,721
Fixed Rate Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date	Oct. 14, 2015
Term	24 months
Loan Amount	$ 50,000
Outstanding Balance	50,000
Original Issue Discount	$ 5,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 8,954
Discount related to Fair value of conversion feature and warrants/shares	$ 49,377
Fixed Rate Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date	Nov. 2, 2015
Term	24 months
Loan Amount	$ 250,000
Outstanding Balance	250,000
Original Issue Discount	$ 25,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 43,079
Discount related to Fair value of conversion feature and warrants/shares	$ 222,723
Fixed Rate Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date	Nov. 10, 2015
Term	24 months
Loan Amount	$ 50,000
Outstanding Balance	50,000
Original Issue Discount	$ 5,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 8,790
Discount related to Fair value of conversion feature and warrants/shares	$ 46,984
Fixed Rate Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date	Nov. 12, 2015
Term	24 months
Loan Amount	$ 215,000
Outstanding Balance	215,000
Original Issue Discount	$ 21,500	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 38,518
Discount related to Fair value of conversion feature and warrants/shares	$ 212,399
Fixed Rate Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date	Nov. 20, 2015
Term	24 months
Loan Amount	$ 200,000
Outstanding Balance	200,000
Original Issue Discount	$ 20,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 37,185
Discount related to Fair value of conversion feature and warrants/shares	$ 200,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date	Dec. 4, 2015
Term	24 months
Loan Amount	$ 170,000
Outstanding Balance	170,000
Original Issue Discount	$ 17,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 37,352
Discount related to Fair value of conversion feature and warrants/shares	$ 170,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date	Dec. 11, 2015
Term	24 months
Loan Amount	$ 360,000
Outstanding Balance	360,000
Original Issue Discount	$ 36,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 75,449
Discount related to Fair value of conversion feature and warrants/shares	$ 360,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member]
Inception Date	Dec. 18, 2015
Term	24 months
Loan Amount	$ 55,000
Outstanding Balance	55,000
Original Issue Discount	$ 5,500	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 11,714
Discount related to Fair value of conversion feature and warrants/shares	$ 55,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date	Dec. 31, 2015
Term	24 months
Loan Amount	$ 100,000
Outstanding Balance	100,000
Original Issue Discount	$ 10,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 20,634
Discount related to Fair value of conversion feature and warrants/shares	$ 100,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Inception Date	Jan. 11, 2016
Term	24 months
Loan Amount	$ 100,000
Outstanding Balance	100,000
Original Issue Discount	$ 10,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 24,966
Discount related to Fair value of conversion feature and warrants/shares	$ 80,034
Fixed Rate Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Inception Date	Jan. 20, 2016
Term	24 months
Loan Amount	$ 50,000
Outstanding Balance	50,000
Original Issue Discount	$ 5,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 9,812
Discount related to Fair value of conversion feature and warrants/shares	$ 40,188
Fixed Rate Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Inception Date	Jan. 29, 2016
Term	24 months
Loan Amount	$ 300,000
Outstanding Balance	300,000
Original Issue Discount	$ 30,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 60,887
Discount related to Fair value of conversion feature and warrants/shares	$ 239,113
Fixed Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Inception Date	Feb. 26, 2016
Term	24 months
Loan Amount	$ 200,000
Outstanding Balance	200,000
Original Issue Discount	$ 20,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 18,260
Discount related to Fair value of conversion feature and warrants/shares	$ 156,048
Fixed Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member]
Inception Date	Mar. 10, 2016
Term	24 months
Loan Amount	$ 125,000
Outstanding Balance	125,000
Original Issue Discount	$ 12,500	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 23,260
Discount related to Fair value of conversion feature and warrants/shares	$ 106,740
Fixed Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Inception Date	Mar. 18, 2016
Term	24 months
Loan Amount	$ 360,000
Outstanding Balance	360,000
Original Issue Discount	$ 36,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 94,992
Discount related to Fair value of conversion feature and warrants/shares	$ 265,008
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty [Member]
Inception Date	Mar. 24, 2016
Term	24 months
Loan Amount	$ 106,667
Outstanding Balance	106,667
Original Issue Discount	$ 10,667	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 15,427
Discount related to Fair value of conversion feature and warrants/shares	$ 91,240
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Inception Date	Mar. 31, 2016
Term	24 months
Loan Amount	$ 167,882
Outstanding Balance	167,882
Original Issue Discount	$ 16,788	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees	$ 2,436
Discount related to Fair value of conversion feature and warrants/shares	$ 165,446
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Inception Date	Apr. 5, 2016
Term	24 months
Loan Amount	$ 10,000
Outstanding Balance	10,000
Original Issue Discount	$ 1,000	[1]
Interest Rate	10.00%	[2]
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 10,000
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Three [Member]
Inception Date	May 24, 2016
Term	7 months
Loan Amount	$ 100,000
Outstanding Balance	100,000
Original Issue Discount	$ 7,000
Interest Rate	0.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 20,368
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Four [Member]
Inception Date	Jun. 15, 2016
Term	6 months
Loan Amount	$ 40,000
Outstanding Balance	40,000
Original Issue Discount
Interest Rate	12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 3,680
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Five [Member]
Inception Date	Jun. 17, 2016
Term	6 months
Loan Amount	$ 40,000
Outstanding Balance	40,000
Original Issue Discount
Interest Rate	12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 3,899
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Six [Member]
Inception Date	Jun. 22, 2016
Term	6 months
Loan Amount	$ 35,000
Outstanding Balance	35,000
Original Issue Discount
Interest Rate	12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 3,373
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Seven [Member]
Inception Date	Jul. 6, 2016
Term	6 months
Loan Amount	$ 85,000
Outstanding Balance	85,000
Original Issue Discount
Interest Rate	12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 15,048
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Eight [Member]
Inception Date	Jul. 29, 2016
Term	6 months
Loan Amount	$ 100,000
Outstanding Balance	100,000
Original Issue Discount
Interest Rate	12.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 25,518
Fixed Rate Convertible Notes [Member] | Convertible Debt Twenty Nine [Member]
Inception Date	Sep. 15, 2016
Term	8 months
Loan Amount	$ 500,000
Outstanding Balance	500,000
Original Issue Discount	$ 40,541
Interest Rate	9.00%
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants/shares	$ 65,972
[1]	The original issue discount is reflected in the first year.
[2]	The annual interest starts accruing in the second year.

Convertible Debt and Other De32

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discount (Details) - USD ($)	May 13, 2016	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Balance at January 1, 2016		$ 277,342
Issuance of convertible debt, face value		2,509,045
Original issued discount		(189,496)
Debt discount from derivative liabilities (embedded conversion option and warrants)		(1,153,817)
Debt discount from shares and warrants issued with the notes		(117,137)
Debt discount from beneficial conversion feature		(20,721)
Deferred financing fees		(270,732)
Conversion of debentures to common shares	$ 117,837	(100,000)
Accretion of interest and amortization of debt discount to interest expense through September 30,		2,808,261
Balance at September 30,		3,742,745
Less: current portion		2,664,334	$ 100,000
Convertible debt, long-term portion		$ 986,843	$ 177,342

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Aug. 29, 2016	May 13, 2016	May 06, 2016	Apr. 22, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Nov. 29, 2015	Dec. 31, 2014	Dec. 12, 2013
Convertible preferred stock, authorized					1,000,000		1,000,000
Convertible preferred stock, par value					$ 0.01		$ 0.01
Convertible preferred stock, shares issued					1,000,000		1,000,000
Common stock, shares outstanding under the plan					30,093,945		30,093,945		34,798,914		22,588,451
Estimated fair value of unvested stock options							$ 459,724
Stock-based compensation expense					$ 90,500	$ 74,864	282,811	$ 185,370
Number of shares connection with cashless exercise of warrants during period				70,000
Number of debt converted into stock		420,849
Valued debt discount to amortized over the term of loan, value		$ 117,837					$ (100,000)
Common stock, par value					$ 0.01		$ 0.01		$ 0.01
Securities Purchase Agreement [Member]
Warrants to purchase, shares					1,125,000		1,125,000
Warrant exercise price per share					$ 0.50		$ 0.50
Warrant expiry term							5 years
Lender [Member]
Conversion of common stock							297,500
Number of debt converted into stock							100,049
Valued debt discount to amortized over the term of loan, value							$ 41,200
Series J Convertible Preferred Stock [Member]
Number of preferred stock issued to conversion of common stock	25
Conversion of common stock	25,000
Number of debt converted into stock	1,112
Pay accrued dividend	$ 445
Remainder of 2016 [Member]
Stock-based compensation expense							90,445
2017 [Member]
Stock-based compensation expense							212,957
2018 [Member]
Stock-based compensation expense							$ 156,322
Three Tranches [Member] | Private Placement [Member]
Sale of common stock, shares							1,125,000
Common stock, par value					0.01		$ 0.01
Purchase price per share					$ 0.40		$ 0.40
Gross proceeds from sale of common stock							$ 450,000
Stock issuance costs related to broker and legal fee							$ 67,035
2015 Equity Incentive Plan [Member]
Common stock reserved for stock option plan					1,800,000		1,800,000
Common stock, shares outstanding under the plan					1,153,750		1,153,750
Options shares granted					646,250		646,250
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan					952,500		952,500					3,000,000
Options shares granted					2,047,500		2,047,500
2015 Nonqualified Stock Option Plan [Member]
Common stock reserved for stock option plan										5,000,000
Common stock, shares outstanding under the plan					2,068,000		2,068,000
Options shares granted					2,932,000		2,932,000
Restricted Stock [Member] | Investor Relations Firms [Member]
Number of common stock shares issued for services							900,000
Series A Junior Participating Preferred Stock [Member]
Number of stock designated					20,000		20,000
Series A Convertible Preferred Stock [Member]
Number of stock designated					313,960		313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated					279,256		279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated					88,098		88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					850		850		850
Convertible preferred stock, par value					$ .01		$ .01		$ .01
Convertible preferred stock, shares issued					300		300		300
Number of stock designated					850		850
Series E Convertible Preferred Stock [Member]
Number of stock designated					500		500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					240,000		240,000		240,000
Convertible preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued					86,570		86,570		86,570
Number of stock designated					240,000		240,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					10,000		10,000		10,000
Convertible preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued					10,000		10,000		10,000
Number of stock designated					10,000		10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					21		21		21
Convertible preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued					21		21		21
Number of stock designated					21		21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					6,250		6,250		6,250
Convertible preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued					3,521		3,521		3,546
Number of stock designated					6,250		6,250
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized					15,000		15,000		15,000
Convertible preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued					6,816		6,816		11,416
Number of stock designated					15,000		15,000
Number of preferred stock issued to conversion of common stock			4,600
Conversion of common stock			4,600,000
Number of debt converted into stock			247,435
Pay accrued dividend			$ 63,413

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Shares, Beginning balance	34,798,914	22,588,451
Shares, Granted	4,294,552	13,337,141
Shares, Exercised	(70,000)
Shares, Expired	(8,813,521)	(996,678)
Shares, Forfeited	(116,000)	130,000
Shares, Ending balance	30,093,945	34,798,914
Exercisable, Beginning balance	31,788,590	16,611,528
Exercisable, Ending balance	28,095,959	31,788,590
Stock Option [Member]
Shares, Beginning balance	5,571,250	3,406,250
Shares, Granted		2,500,000
Shares, Exercised
Shares, Expired	(186,000)	(205,000)
Shares, Forfeited	(116,000)	(130,000)
Shares, Ending balance	5,269,250	5,571,250
Weighted average price per share, Beginning balance	$ 0.44	$ 0.51
Weighted average price per share, Granted		0.40
Weighted average price per share, Exercised
Weighted average price per share, Expired	1	1
Weighted average price per share, Forfeited	0.51	0.70
Weighted average price per share, Ending balance	$ 0.42	$ 0.44
Warrants [Member]
Shares, Beginning balance	29,227,664	19,182,201
Shares, Granted	4,294,552	10,837,141
Shares, Exercised	(70,000)
Shares, Expired	(8,627,521)	(791,678)
Shares, Forfeited
Shares, Ending balance	24,824,695	29,227,664
Weighted average price per share, Beginning balance	$ 0.44	$ 0.49
Weighted average price per share, Granted	0.43	0.40
Weighted average price per share, Exercised	0.31
Weighted average price per share, Expired	0.61	0.31
Weighted average price per share, Forfeited
Weighted average price per share, Ending balance	$ 0.39	$ 0.44

Stockholders' Deficit - Sched35

Stockholders' Deficit - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Exercise Price 1 [Member]
Exercise price range, lower range limit	$ 0.30
Exercise price range, upper range limit	$ 0.39
Options outstanding, number of options | shares	1,675,500
Options outstanding, weighted average remaining contractual life	8 years
Options outstanding, weighted average exercise price	$ 0.30
Options exercisable, number of options | shares	1,248,514
Options exercisable, weighted average remaining contractual life	8 years
Options exercisable, weighted average exercise price	$ 0.30
Exercise Price 2 [Member]
Exercise price range, lower range limit	0.40
Exercise price range, upper range limit	$ 0.49
Options outstanding, number of options | shares	2,786,000
Options outstanding, weighted average remaining contractual life	9 years
Options outstanding, weighted average exercise price	$ 0.40
Options exercisable, number of options | shares	1,165,000
Options exercisable, weighted average remaining contractual life	8 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 0.40
Exercise Price 3 [Member]
Exercise price range, lower range limit	0.50
Exercise price range, upper range limit	$ 0.59
Options outstanding, number of options | shares	226,250
Options outstanding, weighted average remaining contractual life	5 years 10 months 24 days
Options outstanding, weighted average exercise price	$ 0.50
Options exercisable, number of options | shares	226,250
Options exercisable, weighted average remaining contractual life	5 years 10 months 24 days
Options exercisable, weighted average exercise price	$ 0.50
Exercise Price 4 [Member]
Exercise price range, lower range limit	0.60
Exercise price range, upper range limit	$ 0.69
Options outstanding, number of options | shares	385,500
Options outstanding, weighted average remaining contractual life	3 years 4 months 24 days
Options outstanding, weighted average exercise price	$ 0.60
Options exercisable, number of options | shares	385,500
Options exercisable, weighted average remaining contractual life	3 years 4 months 24 days
Options exercisable, weighted average exercise price	$ 0.60
Exercise Price 5 [Member]
Exercise price range, lower range limit	0.70
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	246,000
Options outstanding, weighted average remaining contractual life	2 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 1
Options exercisable, number of options | shares	246,000
Options exercisable, weighted average remaining contractual life	2 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 1
Exercise Price 6 [Member]
Exercise price range, lower range limit	0.30
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	5,269,250
Options outstanding, weighted average remaining contractual life	7 years 9 months 18 days
Options outstanding, weighted average exercise price	$ 0.42
Options exercisable, number of options | shares	3,271,264
Options exercisable, weighted average remaining contractual life	7 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 0.44

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 02, 2016	Oct. 28, 2016	Sep. 30, 2016	Dec. 31, 2015
Common stock, par value			$ 0.01	$ 0.01
Debt principal amount			$ 2,509,045
Subsequent Event [Member] | Consulting Agreement [Member]
Warrants to purchase, shares	660,000
Warrant exercise price per share	$ 0.40
Subsequent Event [Member] | Promissory Note [Member]
Warrants to purchase, shares	625,000	625,000
Warrant exercise price per share		$ 0.40
Debt principal amount		$ 2,000,000
Debt matures date		Oct. 28, 2017
Due to related parties	$ 250,000	$ 250,000
Subsequent Event [Member] | Promissory Note [Member] | Prior Date One [Member]
Debt matures date	Apr. 28, 2017
Principal payment of prior percentage	10.00%
Subsequent Event [Member] | Promissory Note [Member] | Prior Date Two [Member]
Principal payment of prior percentage	4.00%
Debt maturity date description	April 28, 2017 and July28, 2017
Subsequent Event [Member] | Promissory Note [Member] | Prior Date Three [Member]
Principal payment of prior percentage	4.00%
Debt maturity date description	July 28, 2017 and October 28, 2017
Subsequent Event [Member] | Promissory Note [Member] | Minimum [Member]
Due to related parties		250,000
Subsequent Event [Member] | Promissory Note [Member] | Maximum [Member]
Due to related parties		$ 500,000
Subsequent Event [Member] | Tranche One [Member] | Consulting Agreement [Member]
Number of warrants vested, shares	330,000
Subsequent Event [Member] | Tranches Two [Member] | Consulting Agreement [Member]
Number of warrants vested, shares	330,000
Subsequent Event [Member] | Private Placement [Member] | Two Tranches [Member]
Sale of common stock, shares			400,000
Common stock, par value			$ 0.01
Purchase price per share			$ 0.40
Gross proceeds from sale of stock			$ 160,000
Warrants to purchase, shares			400,000
Warrant exercise price per share			$ 0.50
Warrant expire term			5 years